Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR-T / TCR Technology at AACR – Nasdaq
|
Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR–T / TCR Technology at AACR
Nasdaq In a late-breaking poster presentation titled "Dual-switch HER2 CAR–T cells: Small molecule-regulated GO and STOP switches to target solid cancer in vivo," Bellicum scientists tested the novel dual-switch platform in solid tumors by combining both the … |
